ASCO 2023 | Efficacy of sacituzumab govitecan in mUC by Trop-2 expression

Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, takes us through a study which evaluated the efficacy of sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, in patients with previously treated locally advanced or metastatic urothelial carcinoma (mUC) based on Trop-2 expression in archival tumor samples. The analysis included three cohorts (C1, C2, C3) with varying response rates. Trop-2 protein was found to be highly expressed in all cohorts. The objective response rates (ORRs), progression-free survival (PFS), and overall survival (OS) were similar between patients with below or above median Trop-2 expression. These findings suggest that sacituzumab govetican activity in urothelial carcinoma may not depend on Trop-2 expression, but further research is needed to confirm these results. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.